BR112012023382A2 - compostos, composições e métodos de uso de imidazopiridina. - Google Patents

compostos, composições e métodos de uso de imidazopiridina.

Info

Publication number
BR112012023382A2
BR112012023382A2 BR112012023382A BR112012023382A BR112012023382A2 BR 112012023382 A2 BR112012023382 A2 BR 112012023382A2 BR 112012023382 A BR112012023382 A BR 112012023382A BR 112012023382 A BR112012023382 A BR 112012023382A BR 112012023382 A2 BR112012023382 A2 BR 112012023382A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
imidazopyridine compounds
compounds
formulas
Prior art date
Application number
BR112012023382A
Other languages
English (en)
Inventor
Zhang Birrong
Liang Jun
Robarge Kirk
R Magnuson Steven
H Tsui Vickie
Lai Yingjie
Original Assignee
F Hoffmann La Roche Ag T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ag T filed Critical F Hoffmann La Roche Ag T
Publication of BR112012023382A2 publication Critical patent/BR112012023382A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

compostos, composições e métodos de uso de imidazopiridina. a invenção provê compostos de fórmulas ia-ib, estereisômeros ou sais farmaceuticamente aceitáveis dos mesmos, em que a, x, r^ 1^, r ^2^, r ^4^, r ^5^ e r ^16^ são definidos aqui, uma composição farmacêutica que inclui um composto de fórmulas ia-ib e um portador, adjuvante ou veículo famaceuticamente aceitável, e métodos de uso do composto ou a composição em terapia.
BR112012023382A 2010-03-17 2011-03-15 compostos, composições e métodos de uso de imidazopiridina. BR112012023382A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31493210P 2010-03-17 2010-03-17
PCT/EP2011/053826 WO2011113802A2 (en) 2010-03-17 2011-03-15 Imidazopyridine compounds, compositions and methods of use

Publications (1)

Publication Number Publication Date
BR112012023382A2 true BR112012023382A2 (pt) 2018-05-15

Family

ID=43836550

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012023382A BR112012023382A2 (pt) 2010-03-17 2011-03-15 compostos, composições e métodos de uso de imidazopiridina.

Country Status (10)

Country Link
US (1) US20130096104A1 (pt)
EP (1) EP2547338A2 (pt)
JP (1) JP2013522267A (pt)
KR (1) KR20130001272A (pt)
CN (1) CN102869359A (pt)
BR (1) BR112012023382A2 (pt)
CA (1) CA2793024A1 (pt)
MX (1) MX2012010265A (pt)
RU (1) RU2012141536A (pt)
WO (1) WO2011113802A2 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20131197A1 (es) 2008-10-31 2013-11-06 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
JP5822934B2 (ja) 2010-09-15 2015-11-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アザベンゾチアゾール化合物、組成物及び使用方法
EP2638018A1 (en) 2010-11-09 2013-09-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
JP2013542966A (ja) * 2010-11-19 2013-11-28 エフ．ホフマン−ラ ロシュ アーゲー ピラゾロピリジンならびにｔｙｋ２阻害剤としてのピラゾロピリジン及びそれらの使用
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
US9085578B2 (en) 2012-02-20 2015-07-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3040336T3 (da) 2012-03-02 2020-06-22 Sareum Ltd Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
JP6197031B2 (ja) 2012-05-24 2017-09-13 セルゾーム リミティッド Ｔｙｋ２阻害剤としてのヘテロシクリルピリミジン類似体
US8809359B2 (en) * 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
AU2013347539B2 (en) 2012-11-16 2017-06-15 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
KR102191084B1 (ko) 2013-09-03 2020-12-15 사름 리미티드 약제학적 화합물
CN103804380B (zh) * 2014-01-24 2016-05-18 温州医科大学 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法
JP6526065B2 (ja) 2014-02-28 2019-06-05 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
PE20170663A1 (es) 2014-05-23 2017-05-22 Hoffmann La Roche Compuestos de 5- cloro- 2- difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
ES2930585T3 (es) 2015-02-27 2022-12-19 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
CN105884777B (zh) * 2015-06-09 2017-11-10 温州医科大学 一种作用于EGFR敏感突变激酶EGFRL858R，EGFR(d746‑750)的6‑取代氨基嘌呤类化合物及其应用
CN107162987A (zh) * 2016-03-07 2017-09-15 宜昌人福药业有限责任公司 一种利匹韦林的工业化合成方法及中间体化合物
WO2017162604A1 (en) 2016-03-21 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and treatment of solar lentigo
CN107629054A (zh) * 2016-07-18 2018-01-26 苏州赛乐生物科技有限公司 一种6‑溴嘌呤的合成方法
WO2018075937A1 (en) * 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
CN108373476B (zh) * 2017-01-13 2021-06-01 成都地奥制药集团有限公司 一种激酶抑制剂及其制备和应用
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
WO2021057696A1 (zh) * 2019-09-27 2021-04-01 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
ES517193A0 (es) * 1981-11-10 1983-12-01 Wellcome Found Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
ZA828213B (en) * 1981-11-10 1984-06-27 Wellcome Found New bicyclic compounds,processes for their preparation and pharmaceutical formulations containing such compounds
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1991003489A1 (en) 1989-09-08 1991-03-21 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
PT659439E (pt) 1993-12-24 2002-04-29 Merck Patent Gmbh Imunoconjugados
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
DE69507956T2 (de) 1994-07-21 1999-09-09 Akzo Nobel Nv Zyklische keton peroxyde zubereitungen
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
EP0831880A4 (en) 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
ATE227283T1 (de) 1996-07-13 2002-11-15 Glaxo Group Ltd Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
PT980244E (pt) 1997-05-06 2003-10-31 Wyeth Corp Utilizacao de compostos de quinazolina para o tratamento da doenca policistica renal
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
WO2000031048A1 (en) 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
DK1221444T3 (da) * 1999-07-02 2005-11-14 Eisai Co Ltd Kondenserede imidazolforbindelser og lægemidler mod diabetes mellitus
US7129239B2 (en) * 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
CA2502429A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
WO2007039797A1 (en) * 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
NZ574513A (en) * 2006-08-08 2012-02-24 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of e1 activating enzymes
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
ES2481715T3 (es) * 2009-02-06 2014-07-31 Janssen Pharmaceuticals, Inc. Compuestos heterocíclicos bicíclicos sustituidos novedosos como moduladores de gamma-secretasa
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類

Also Published As

Publication number Publication date
CN102869359A (zh) 2013-01-09
JP2013522267A (ja) 2013-06-13
CA2793024A1 (en) 2011-09-22
MX2012010265A (es) 2012-10-01
RU2012141536A (ru) 2014-04-27
WO2011113802A3 (en) 2012-08-02
EP2547338A2 (en) 2013-01-23
WO2011113802A2 (en) 2011-09-22
US20130096104A1 (en) 2013-04-18
KR20130001272A (ko) 2013-01-03

Similar Documents

Publication Publication Date Title
BR112012023382A2 (pt) compostos, composições e métodos de uso de imidazopiridina.
CY1124117T1 (el) Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων
CL2013000351A1 (es) Compuestos derivados de 2-(arilamino)-3h-imidazo[4,5-b]piridina-6-carboxamida; inhibidores de la prostaglandina e2 sintasa-1 microsomal (mpges-1) composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de enfermedades inflamatorias.
MX350597B (es) 4- (8 - metoxi - 1 - ( (1 - metoxipropan - 2 - il) - 2 - (tetrahidro - 2h - piran - 4 - il) - 1 h - imidazo [4,5-c] quinolin -7 - il ) -3,5 - dimetilisoxazol y su uso como inhibidor de bromodominio.
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
GEP20166432B (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
NZ703064A (en) Inhibitors of hepatitis c virus
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
BR112012026950A2 (pt) composto, e, uso de um composto
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112014010407A2 (pt) compostos de azetidina, composições e seu uso como inibidores de hidrolase de epóxido solúvel
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201100030A1 (ru) Пиразольные соединения 436
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
EA201270590A1 (ru) Ингибиторы акт

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.